FIELD: experimental medicine; dermatology.
SUBSTANCE: proposed method comprises 5% imiquimod cream application on epilated back skin of female mice aged 9 weeks in a daily dose of 62.5 mg/cm2 per mouse for 7 days. Seven-day course is repeated with applying 5% imiquimod cream in the same dose.
EFFECT: method is easy to reproduce, is well tolerated by animals, enables to create an adequate model of chronic psoriasis-like inflammation with maximally formed and pronounced inflammation, having a chronic nature, and minimal risk of hair regrowth in mice at stages of inflammation assessment, allows to objectively assess inflammation at different stages without systemic action of preparation on animal organism.
1 cl, 3 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF FORMING A LABORATORY MODEL OF PSORIASIS IN IMIQUIMOD-INDUCED INFLAMMATION IN EXPERIMENTAL ANIMALS | 2020 |
|
RU2736000C1 |
| METHOD FOR EVALUATING THE ANTIPSORIATIC EFFECT OF AN EXTERNAL AGENT ON A LABORATORY MODEL OF IMIQUIMOD-INDUCED PSORIASIS | 2021 |
|
RU2764549C1 |
| THE METHOD OF PRODUCTION OF INTERLEUKIN-36 RECEPTOR ANTAGONIST WITH CLEAVED N-TERMINAL METHIONINE, ESCHERICHIA COLI BL21[DE3] STRAIN PRODUCING INTERLEUKIN-36 RECEPTOR ANTAGONIST WITH CLEAVED N-TERMINAL METHIONINE (VARIANTS), METHOD OF THEIR CONSTRUCTION, PLASMID VECTORS pBAD15A AND pET15A AND DNA SEQUENCE FOR THEIR CONSTRUCTION | 2017 |
|
RU2672816C9 |
| PHARMACEUTICAL COMPOSITION HAVING THERAPEUTIC EFFECT IN VARIOUS SKIN PATHOLOGIES | 2019 |
|
RU2694059C1 |
| PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PSORIASIS | 2020 |
|
RU2742879C1 |
| DRUG FOR TREATMENT OF PSORIASIS AND ITS PRODUCTION METHOD | 2019 |
|
RU2785038C2 |
| METHOD FOR REVERSING GENETICALLY DETERMINED INHIBITION OF GROWTH OF A MALIGNANT TUMOR IN EXPERIMENT | 2019 |
|
RU2718671C1 |
| DERIVATIVE OF THE CLASS OF N-GLYCOSIDES INDOLO[2,3-A]PYRROLO[3,4-C]CARBAZOLE-5,7-DIONE - N-{12-(β-D-XYLOPYRANOSYL)-5,7-DIOXO-INDOLO[2,3-A]PYRROLO[3,4-C]CARBAZOL-6-YL} PYRIDINE-2-CARBOXAMIDE, WHICH HAS CYTOTOXIC AND ANTITUMOR ACTIVITY | 2017 |
|
RU2667906C1 |
| BIOMEDICAL CELL PRODUCT WITH SPECIFIC ANTITUMOR ACTIVITY, REPRESENTED BY POPULATIONS OF LYMPHOKINE-ACTIVATED KILLERS AND ANTI-HER2 CAR-γδΤ-OIL AND ANTI-HER2 CAR-T-NK | 2022 |
|
RU2786210C1 |
| USE OF N-(6,8,8-TRIMETHYL-8,9-DIHYDROFURO[3,2-H]QUINOLIN-5-YL)ACETAMIDE AS AN AGENT FOR PHOTOTHERAPY OF PSORIASIS AND PSORIATIC ARTHRITIS | 2018 |
|
RU2686692C1 |
